Inventor
RAUM TOBIAS
DE60 patents
⚠️ This page may combine multiple inventors who share the name “RAUM TOBIAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AMGEN RES MUNICH GMBH
32 patentsUS9340621B2May 17, 2016
Binding molecules for BCMA and CD3
AMGEN RES MUNICH GMBH91 citations98
US10294300B2May 21, 2019
Antibody constructs for DLL3 and CD3
AMGEN RES MUNICH GMBH37 citations97
US9150664B2Oct 6, 2015
Binding molecules for BCMA and CD3
AMGEN RES MUNICH GMBH64 citations97
US10301391B2May 28, 2019
BCMA and CD3 bispecific T cell engaging antibody constructs
AMGEN RES MUNICH GMBH28 citations93
US9598500B2Mar 21, 2017
Binding molecules for BCMA and CD3
AMGEN RES MUNICH GMBH22 citations93
US10519241B2Dec 31, 2019
Antibody constructs for EGFRVIII and CD3
AMGEN RES MUNICH GMBH16 citations92
US9982063B2May 29, 2018
Pharmaceutical compositions with resistance to soluble CEA
AMGEN RES MUNICH GMBH14 citations90
US11591396B2Feb 28, 2023
Antibody constructs for DLL3 and CD3
AMGEN RES MUNICH GMBH5 citations85
US10752694B2Aug 25, 2020
Binding molecules for BCMA and CD3
AMGEN RES MUNICH GMBH11 citations85
US10766969B2Sep 8, 2020
Binding molecules for BCMA and CD3
AMGEN RES MUNICH GMBH8 citations83
US10683351B2Jun 16, 2020
Antibody constructs for DLL3 and CD3
AMGEN RES MUNICH GMBH4 citations83
US10781264B2Sep 22, 2020
PSMA and CD3 bispecific T cell engaging antibody constructs
AMGEN RES MUNICH GMBH8 citations82
US10059766B2Aug 28, 2018
Antibody constructs for CDH19 and CD3
AMGEN RES MUNICH GMBH9 citations82
US11661462B2May 30, 2023
Optimized cross-species specific bispecific single chain antibody contructs
AMGEN RES MUNICH GMBH4 citations73
US11434302B2Sep 6, 2022
Bispecific T cell engaging antibody constructs
AMGEN RES MUNICH GMBH7 citations73
US11692031B2Jul 4, 2023
Antibody constructs for CLDN18.2 and CD3
AMGEN RES MUNICH GMBH6 citations71
US11472886B2Oct 18, 2022
Cross-species-specific PSMAxCD3 bispecific single chain antibody
AMGEN RES MUNICH GMBH3 citations71
US11352433B2Jun 7, 2022
BCMA and CD3 bispecific T cell engaging antibody constructs
AMGEN RES MUNICH GMBH2 citations71
US11155629B2Oct 26, 2021
Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3
AMGEN RES MUNICH GMBH2 citations71
US9695250B2Jul 4, 2017
Pharmaceutical compositions with resistance to soluble CEA
AMGEN RES MUNICH GMBH4 citations71
US11447567B2Sep 20, 2022
Antibody constructs for FLT3 and CD3
AMGEN RES MUNICH GMBH4 citations69
US10851170B2Dec 1, 2020
Antibody constructs for CD70 and CD3
AMGEN RES MUNICH GMBH3 citations67
US12435139B2Oct 7, 2025
Antibody constructs for DLL3 and CD3
AMGEN RES MUNICH GMBH0 citations62
US12304952B2May 20, 2025
Antibody constructs for DLL3 and CD3
AMGEN RES MUNICH GMBH0 citations62
US11987633B2May 21, 2024
Cross-species-specific single domain bispecific single chain antibody
AMGEN RES MUNICH GMBH1 citations62
US12428491B2Sep 30, 2025
PSMA and CD3 bispecific T cell engaging antibody constructs
AMGEN RES MUNICH GMBH0 citations61
US12152078B2Nov 26, 2024
Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3
AMGEN RES MUNICH GMBH0 citations61
US11498964B2Nov 15, 2022
Antibody constructs for CDH19 and CD3
AMGEN RES MUNICH GMBH1 citations61
US12281172B2Apr 22, 2025
Cross-species-specific PSMAxCD3 bispecific single chain antibody
AMGEN RES MUNICH GMBH0 citations60
US11925684B2Mar 12, 2024
Compositions comprising cross-species-specific antibodies and uses thereof
AMGEN RES MUNICH GMBH0 citations60
US11884720B2Jan 30, 2024
Antibody constructs for MSLN and CD3
AMGEN RES MUNICH GMBH1 citations60
US11926666B2Mar 12, 2024
Bispecific antibody constructs for CDH3 and CD3
AMGEN RES MUNICH GMBH0 citations57
AMGEN INC
6 patentsUS9765157B2Sep 19, 2017
Antibody constructs for CDH19 and CD3
AMGEN INC13 citations82
US12281176B2Apr 22, 2025
Binding molecules for BCMA and CD3
AMGEN INC1 citations74
US12297292B2May 13, 2025
Antibody constructs for CDH19 and CD3
AMGEN INC2 citations72
US12281175B2Apr 22, 2025
Binding molecules for BCMA and CD3
AMGEN INC0 citations62
US12441796B2Oct 14, 2025
Antibody constructs for CDH19 and CD3
AMGEN INC0 citations61
US12258404B2Mar 25, 2025
Bispecific antibody construct directed to MUC17 and CD3
AMGEN INC0 citations59
MICROMET AG
5 patentsUS7919089B2Apr 5, 2011
Pharmaceutical composition comprising a bispecific antibody for EpCAM
MICROMET AG57 citations95
US8017748B2Sep 13, 2011
Antibody neutralizers of human granulocyte macrophage colony stimulating factor
MICROMET AG56 citations93
US7227002B1Jun 5, 2007
Human antibodies that bind human 17-A1/EpCAM tumor antigen
MICROMET AG52 citations93
US7435549B1Oct 14, 2008
Method of identifying binding site domains that retain the capacity of binding to an epitope
MICROMET AG51 citations88
US7632925B2Dec 15, 2009
Antibodies that bind human 17-A1/EpCAM tumor antigen
MICROMET AG17 citations84
KUFER PETER
4 patentsUS8784821B1Jul 22, 2014
Human-anti-human cd3 binding molecules
KUFER PETER63 citations95
US9587036B2Mar 7, 2017
Cross-species-specific PSMAxCD3 bispecific single chain antibody
KUFER PETER24 citations92
US10981998B2Apr 20, 2021
Cross-species-specific single domain bispecific single chain antibody
KUFER PETER5 citations83
US8790645B2Jul 29, 2014
Pharmaceutical composition comprising a bispecific antibody for EpCAM
KUFER PETER10 citations81
KISCHEL ROMAN
1 patentLUTTERBUESE RALF
1 patentHOFFMANN PATRICK
1 patentShowing the top 50 of 60 patents by PatentIndex Score.